{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+IV+infusion&page=12", "query": { "intervention": "Placebo IV infusion", "page": 12 }, "page_size": 10 }, "pagination": { "page": 12, "page_size": 10, "total_count": 1859, "total_pages": 186, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+IV+infusion&page=13&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+IV+infusion&page=11&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T21:31:28.285Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04501978", "title": "ACTIV-3: Therapeutics for Inpatients With COVID-19", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Covid19" ], "interventions": [ { "name": "LY3819253", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Remdesivir", "type": "BIOLOGICAL" }, { "name": "VIR-7831", "type": "BIOLOGICAL" }, { "name": "BRII-196/BRII-198", "type": "BIOLOGICAL" }, { "name": "AZD7442", "type": "BIOLOGICAL" }, { "name": "MP0420", "type": "DRUG" }, { "name": "PF-07304814", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2753, "start_date": "2020-08-04", "completion_date": "2023-07-14", "has_results": false, "last_update_posted_date": "2023-08-25", "last_synced_at": "2026-10-14T21:31:28.285Z", "location_count": 98, "location_summary": "Tucson, Arizona • Chula Vista, California • Fresno, California + 64 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Chula Vista", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "La Mesa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04501978" }, { "nct_id": "NCT00559338", "title": "Impact of Nesiritide Infusion for Decompensated Heart Failure in the Emergency Department", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Heart Failure, Congestive", "Cardiomyopathy" ], "interventions": [ { "name": "recombinant B-type, natriuretic peptide", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 104, "start_date": "2003-12", "completion_date": "2005-04", "has_results": false, "last_update_posted_date": "2007-11-16", "last_synced_at": "2026-10-14T21:31:28.285Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00559338" }, { "nct_id": "NCT01362400", "title": "A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "IPI 504 plus Docetaxel", "type": "DRUG" }, { "name": "Placebo plus Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Infinity Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 226, "start_date": "2011-05", "completion_date": "2014-04", "has_results": false, "last_update_posted_date": "2014-05-19", "last_synced_at": "2026-10-14T21:31:28.285Z", "location_count": 41, "location_summary": "Chandler, Arizona • Tucson, Arizona • Orange, California + 38 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "Oxnard", "state": "California" }, { "city": "Rancho Cucamonga", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01362400" }, { "nct_id": "NCT05488340", "title": "A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urinary Tract Infections" ], "interventions": [ { "name": "LBP-EC01 0.1 x IV dose", "type": "DRUG" }, { "name": "LBP-EC01 0.01x IV Dose", "type": "DRUG" }, { "name": "LBP-EC01 IV Infusion Dose", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "LBP-EC01", "type": "DRUG" }, { "name": "TMP/SMX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Locus Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "FEMALE", "summary": "18 Years to 75 Years · Female only" }, "enrollment_count": 318, "start_date": "2022-07-13", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-14T21:31:28.285Z", "location_count": 17, "location_summary": "Fresno, California • Lancaster, California • Los Angeles, California + 13 more", "locations": [ { "city": "Fresno", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Montebello", "state": "California" }, { "city": "Murrieta", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05488340" }, { "nct_id": "NCT06186219", "title": "Recapturing Immune Tolerance to Pegloticase for the Management of Tophaceous Gout", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Tophaceous Gout" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2024-04-10", "completion_date": "2024-11-22", "has_results": false, "last_update_posted_date": "2025-11-20", "last_synced_at": "2026-10-14T21:31:28.285Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06186219" }, { "nct_id": "NCT06071767", "title": "Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "ChAdOx1.tHIVconsv1", "type": "BIOLOGICAL" }, { "name": "ChAdOx1.HIVconsv62", "type": "BIOLOGICAL" }, { "name": "MVA.tHIVconsv3", "type": "BIOLOGICAL" }, { "name": "MVA.tHIVconsv4", "type": "BIOLOGICAL" }, { "name": "Vesatolimod (VES)", "type": "DRUG" }, { "name": "GS-5423", "type": "DRUG" }, { "name": "GS-2872", "type": "DRUG" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2024-04-01", "completion_date": "2029-08-01", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-10-14T21:31:28.285Z", "location_count": 9, "location_summary": "San Diego, California • Atlanta, Georgia • Chicago, Illinois + 6 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT06071767" }, { "nct_id": "NCT00531817", "title": "A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Permitted DMARDs", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 619, "start_date": "2007-10", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2012-08-20", "last_synced_at": "2026-10-14T21:31:28.285Z", "location_count": 156, "location_summary": "Birmingham, Alabama • Montgomery, Alabama • Lake Havasu City, Arizona + 135 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Lake Havasu City", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00531817" }, { "nct_id": "NCT01410227", "title": "Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Von Willebrand Disease" ], "interventions": [ { "name": "Recombinant von Willebrand factor (rVWF)", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Recombinant factor VIIII (rFVIII)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Baxalta now part of Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 49, "start_date": "2011-11-01", "completion_date": "2014-02-01", "has_results": true, "last_update_posted_date": "2021-05-19", "last_synced_at": "2026-10-14T21:31:28.285Z", "location_count": 10, "location_summary": "Sacramento, California • Miami, Florida • Peoria, Illinois + 7 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Newark", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01410227" }, { "nct_id": "NCT06111586", "title": "Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and Children on Top of Insulin Therapy (FABULINUS)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type 1 Diabetes Mellitus" ], "interventions": [ { "name": "Frexalimab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Insulin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "35 Years", "sex": "ALL", "summary": "6 Years to 35 Years" }, "enrollment_count": 197, "start_date": "2023-12-11", "completion_date": "2030-10-29", "has_results": false, "last_update_posted_date": "2026-06-29", "last_synced_at": "2026-10-14T21:31:28.285Z", "location_count": 14, "location_summary": "San Francisco, California • Aurora, Colorado • Gainesville, Florida + 11 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06111586" }, { "nct_id": "NCT00089986", "title": "GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis In Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sepsis" ], "interventions": [ { "name": "Intravenous GR270773- Phospholipid Emulsion", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1415, "start_date": "2004-09-01", "completion_date": "2007-04-15", "has_results": true, "last_update_posted_date": "2017-08-21", "last_synced_at": "2026-10-14T21:31:28.285Z", "location_count": 132, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 110 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Bentonville", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00089986" } ] }